CLINICAL RESEARCH: TREATMENT OF PATENT FORAMEN OVALE
Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients
Andreas Wahl, MD*,
Ulrike Krumsdorf, MD ,
Bernhard Meier, MD*,
Horst Sievert, MD,
Stephan Ostermayer, MD,*,
Kai Billinger, MD,
Markus Schwerzmann, MD*,
Ulf Becker, MD*,
Christian Seiler, MD*,
Marcel Arnold, MD ,
Heinrich P. Mattle, MD and
Stephan Windecker, MD
* Cardiology
Neurology, University Hospital, Bern, Switzerland
Cardiovascular Center, Frankfurt, Germany
Manuscript received June 28, 2004;
accepted October 18, 2004.
* Reprint requests and correspondence: Dr. Stephan Windecker, Director, Invasive Cardiology, Swiss Cardiovascular Center, Bern University Hospital, CH-3010, Bern, Switzerland (Email: stephan.windecker{at}insel.ch).
OBJECTIVES: This study sought to investigate the safety and efficacy of transcatheter treatment of atrial septal aneurysm (ASA) associated with patent foramen ovale (PFO).
BACKGROUND: Patients with both ASA and PFO are at high risk for recurrent paradoxical embolism.
METHODS: The procedural, echocardiographic, and clinical outcomes of 141 patients with ASA + PFO and  1 paradoxical embolic event undergoing transcatheter treatment were compared with 220 patients with PFO alone.
RESULTS: Device success (ASA + PFO, 99.3%; PFO alone, 99.5%; p = 0.75) and procedural complications (ASA + PFO, 0.7%; PFO alone, 3.2%; p = 0.12) were similar in both groups. Maximal atrial septal excursion in patients with ASA + PFO decreased from 16 ± 4 mm before to 4 ± 3 mm after the intervention (p < 0.0001). At 6 months follow-up, right-to-left shunt was abolished in 120 (86%) patients with ASA + PFO, compared to 187 (85%) patients with PFO alone (p = 0.80). Freedom from recurrent transient ischemic attack, stroke, and peripheral embolism at 4 years was 95% (ASA + PFO) and 94% (PFO alone, p = 0.70), respectively. A residual right-to-left shunt after the intervention was the only predictor for recurrence (hazard ratio [HR] 6.9; 95% confidence interval [CI] 1.3 to 36.9, p < 0.03) in patients with ASA + PFO.
CONCLUSIONS: Transcatheter treatment of ASA + PFO is safe and effective in patients with paradoxical embolism. The procedure effectively abolishes right-to-left shunt and decreases atrial septal mobility. Long-term prevention of recurrent events appears favorable when compared to patients with PFO alone.
|
Abbreviations and Acronyms
| | ASA = atrial septal aneurysm | | CI = confidence interval | | HR = hazard ratio | | PFO = patent foramen ovale | | TEE = transesophageal echocardiography | | TIA = transient ischemic attack |
|
This article has been cited by other articles:
|
|
|
|
 
J. Wohrle, M. Kochs, J. Spiess, T. Nusser, V. Hombach, and N. Merkle
Impact of Percutaneous Device Implantation for Closure of Patent Foramen Ovale on Valve Insufficiencies
Circulation,
June 16, 2009;
119(23):
3002 - 3008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Jesurum, C. J. Fuller, J. Renz, K. A. Krabill, M. P. Spencer, and M. Reisman
Diagnosis of Secondary Source of Right-to-Left Shunt With Balloon Occlusion of Patent Foramen Ovale and Power M-Mode Transcranial Doppler
J. Am. Coll. Cardiol. Intv.,
June 1, 2009;
2(6):
561 - 567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Reisman
Patent Foramen Ovale: Closing Arguments
J. Am. Coll. Cardiol. Intv.,
May 1, 2009;
2(5):
412 - 414.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Wahl, T. Tai, F. Praz, M. Schwerzmann, C. Seiler, K. Nedeltchev, S. Windecker, H. P. Mattle, and B. Meier
Late Results After Percutaneous Closure of Patent Foramen Ovale for Secondary Prevention of Paradoxical Embolism Using the Amplatzer PFO Occluder Without Intraprocedural Echocardiography: Effect of Device Size
J. Am. Coll. Cardiol. Intv.,
February 1, 2009;
2(2):
116 - 123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Sorajja and R. A. Nishimura
Patent Foramen Ovale Closure Without Echocardiography: Are We Closing the Door Too Fast Too Soon?
J. Am. Coll. Cardiol. Intv.,
February 1, 2009;
2(2):
124 - 126.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Wahl and B Meier
Patent foramen ovale and ventricular septal defect closure
Heart,
January 1, 2009;
95(1):
70 - 82.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Windecker and B. Meier
Patent Foramen Ovale and Cryptogenic Stroke: To Close or Not to Close? Closure: What Else!
Circulation,
November 4, 2008;
118(19):
1989 - 1997.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Messe and S. E. Kasner
Patent Foramen Ovale in Cryptogenic Stroke: Not to Close
Circulation,
November 4, 2008;
118(19):
1999 - 2004.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Wahl, M Kunz, A Moschovitis, T Nageh, M Schwerzmann, C Seiler, H P Mattle, S Windecker, and B Meier
Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism
Heart,
March 1, 2008;
94(3):
336 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Burch, M. F. Davidson, and S. J. Pereira
Use of Transesophageal Echocardiography in the Evaluation and Surgical Treatment of a Patient with an Aneurysmal Interatrial Septum and an Intracardiac Thrombus Traversing a Patent Foramen Ovale
Anesth. Analg.,
March 1, 2008;
106(3):
769 - 770.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Spies, R. Strasheim, I. Timmermanns, and R. Schraeder
Patent foramen ovale closure in patients with cryptogenic thrombo-embolic events using the Cardia PFO occluder
Eur. Heart J.,
February 1, 2006;
27(3):
365 - 371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Meier
Patent Foramen Ovale, Guilty But Only as a Gang Member and for a Lesser Crime
J. Am. Coll. Cardiol.,
January 17, 2006;
47(2):
446 - 448.
[Full Text]
[PDF]
|
|
|
|
